Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Researchers develop CRISPR/Cas9 hemophilia A murine model

July 11, 2019

Phase I/II data presented for BIVV-001 in hemophilia A

July 10, 2019

Shanghai Meiyue Biotech presents new thrombin inhibitors

July 2, 2019

BioCryst opens enrollment in phase I study of oral factor D inhibitor BCX-9930

June 28, 2019

FDA approves Doptelet for chronic immune thrombocytopenia

June 28, 2019

EC grants marketing authorization for Doptelet for severe thrombocytopenia in adults with CLD

June 26, 2019

European Commission approves Esperoct for adolescents and adults with hemophilia A

June 21, 2019

Ultomiris approved in Japan for PNH

June 19, 2019

PB-2452 reverses ticagrelor antiplatelet activity in older and elderly patients in phase IIa trial

June 18, 2019

Luspatercept MOA: Up for grabs?

June 18, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 7, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.